1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the three months ended June 30, 2024, the following directors and officers (as defined in Rule-1(f) of the Exchange Act) adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408 of Regulation S-K.
−Removed: • Gail Boudreaux , President and Chief Executive Officer and member of our Board of Directors, adopted a stock trading plan on April 19, 2024 , pursuant to which she may sell up to 34,000 shares of our common stock prior to October 31, 2024 .
−Removed: • Ramiro Peru , a member of our Board of Directors , adopted a stock trading plan on May 6, 2024 , pursuant to which he may sell up to 753 shares of the Company’s common stock prior to May 6, 2025 .
−Removed: • Mark Kaye , Executive Vice President and Chief Financial Officer , adopted a stock trading plan on April 22, 2024 , pursuant to which he may sell up to 6,758 shares of our common stock prior to February 28, 2025 .
−Removed: Each of these trading plans was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in our securities.
+Added: On September 26, 2024 , Mark Kaye , our Executive Vice President and Chief Financial Officer , terminated his Rule 10b5-1 stock trading plan, which was adopted on April 22, 2024, pursuant to which he had authorized the sale of up to 6,758 shares of our common stock.
+Added: This trading plan was entered into and terminated in accordance with the Company’s policies regarding transactions in our securities.
+Added: No sales occurred pursuant to this Rule 10b5-1 trading plan prior to termination.
+Added: During the three months ended September 30, 2024, none of our other directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408 of Regulation S-K.
3.1 Amended and Restated Articles of Incorporation of the Company, as amended and restated effective June 27, 2022, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 28, 2022.
3.2 Bylaws of the Company, as amended effective October 4, 2023, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 5, 2023.
−Removed: Form of 5.150% Notes due 2029, incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on May 30, 2024.
−Removed: 375 % Notes due 20 34 , incorporated by reference to Exhibit 4.
−Removed: 3 to the Company's Current Report on Form 8-K filed on May 30, 2024.
−Removed: Form of 5.650% Notes due 2054, incorporated by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on May 30, 2024.
4.5 Upon the request of the U.S.
15 unchanged sentences
ELEVANCE HEALTH, INC.
−Removed: July 17, 2024 By:
+Added: October 17, 2024 By:
/ S / M ARK B.
1 unchanged sentence
(Duly Authorized Officer and Principal Financial Officer)
−Removed: July 17, 2024 By:
+Added: October 17, 2024 By:
/ S / R ONALD W.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.